Patritumab deruxtecan Datasheet DC Chemicals

Description	Patritumab deruxtecan (HER3-DXd) is an antibody-drug conjugate (ADC) consisting of a fully human anti-HER3 IgG1 monoclonal antibody Patritumab (HY-P99275) attached to a topoisomerase I inhibitor payload via a tetrapeptide-based cleavable linker. Patritumab deruxtecan shows anticancer activity[1].
Cat.No	A274
Name	Patritumab deruxtecan

Chemical Properties

CAS	2227102-46-5
Synonyms
pH value	Corresponds to reference standard: PASS
Non-reduced CE-SDS	>95%
SEC-HPLC	>95%
Isoelectric Point	Corresponds to reference standard
Bacterial Endotoxins Test
Residual Proteins of Host Cell
Exogenous Residual DNA
Residual protein A
Biological Activity
Osmolality	Corresponds to reference standard: PASS
Peptide mapping	Corresponds to reference standard: PASS
N-terminal sequence	Corresponds to reference standard: PASS

References

[1]. Koyama K, et al. Patritumab deruxtecan (HER3-DXd), a novel HER3 directed antibody drug conjugate, exhibits in vitro activity against breast cancer cells expressing HER3 mutations with and without HER2 overexpression. PLoS One. 2022 May 3;17(5):e0267027.

Return Policy

If you are in any way unsatisfied with your purchase, you may return any item(s) within 365 days of its original purchase date.

Please provide your Order Number in the email. We strive to reply to all email inquiries within one business day.

Tel: +86-21-58447131
Fax: +86-21-61642470

Email:
sales@dcchemicals.com
order@dcchemicals.com

Website:
www.dcchemicals.com